Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Open accessAbstract
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event. Between December 2015 and April 2016, we conducted a retrospective study in centres experienced in ICI use. We report the main features of ICI–ILD with a focus on clinical presentation, radiological patterns and therapeutic strategies. We identified 64 (3.5%) out of 1826 cancer patients with ICI–ILD. Patients mainly received programmed cell death-1 inhibitors. ILD usually occurred in males, and former or current smokers, with a median age of 59 years. We observed 65.6% grade 2/3 severity, 9.4% grade 4 severity and 9.4% fatal ILD. The median (range) time from initiation of immunotherapy to ILD was 2.3 (0.2−27.4) months. Onset tended to occur earlier in lung cancer versus melanoma: median 2.1 and 5.2 months, respectively (p=0.02). Ground-glass opacities (81.3%) were the predominant lesions, followed by consolidations (53.1%). Organising pneumonia (23.4%) and hypersensitivity pneumonitis (15.6%) were the most common patterns. Overall survival at 6 months was 58.1% (95% CI 37.7–73.8%). ICI–ILD often occurs early and displays suggestive radiological features. As there is no clearly identified risk factor, oncologists need to diagnose and adequately treat this adverse event.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Checkpoint inhibitors used as cancer immunotherapy can cause inflammatory interstitial lung disease.
“checkpoint inhibitors used as cancer immunotherapy can cause inflammatory ILD (132)”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · see citing works
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,320 · see citing works
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · see citing works
Self-citationPneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215 · see citing works
Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
Nishino, M., Giobbie‐Hurder, A., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2453 · Cited by 763 · see citing works
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · see citing works
Nishino, M., Ramaiya, N. H., Awad, M. M., Sholl, L. M., Maattala, J. A., Taibi, M., Hatabu, H., Ott, P. A., Armand, P. A., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1320 · Cited by 500 · see citing works
Interstitial Lung Disease Induced by Drugs and Radiation
Camus, P., Fanton, A., Bonniaud, P., Camus, C., & Foucher, P. (2004) · Respiration · doi:10.1159/000079633 · Cited by 394 · see citing works
Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
Nishino, M., Sholl, L. M., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505197 · Cited by 373 · see citing works
Bronstein, Y., Ng, C. S., Hwu, P., & Hwu, W. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.6198 · Cited by 247 · see citing works
What Every Radiologist Should Know about Idiopathic Interstitial Pneumonias
Mueller‐Mang, C., Große, C., Schmid, K., et al. (2007) · Radiographics · doi:10.1148/rg.273065130 · Cited by 202 · see citing works
Inoue, A., Kunitoh, H., Sekine, I., et al. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00783-5 · Cited by 190 · see citing works
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza‐Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182 · see citing works
Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Barjaktarević, I., Qadir, N., Suri, A., Santamauro, J. T., & Stover, D. E. (2013) · CHEST Journal · doi:10.1378/chest.12-1467 · Cited by 110 · see citing works
A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy
Roychowdhury, D. F., Cassidy, C. A., Peterson, P. M., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1016214032272 · Cited by 92 · see citing works
Pulmonary Toxicity Associated With Erlotinib
Liu, V., White, D. A., Zakowski, M. F., et al. (2007) · CHEST Journal · doi:10.1378/chest.07-0050 · Cited by 81 · see citing works
Créquit, P., Wislez, M., Fleury‐Feith, J., Rozensztajn, N., Jabot, L., Friard, S., Lavolé, A., Gounant, V., Fillon, J., Antoine, M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000577 · Cited by 52 · see citing works
Self-citationImmune-mediated respiratory adverse events of checkpoint inhibitors
Tabchi, S., Messier, C., & Blais, N. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000291 · Cited by 50 · see citing works
Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment
Grande, C., Villanueva, M. J., Huidobro, G., & Casal, J. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0106-4 · Cited by 48 · see citing works
Chiang, C., Chen, Y., Wu, M., et al. (2016) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2016.01.008 · Cited by 43 · see citing works
Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma
Gounant, V., Brosseau, S., Naltet, C., Opsomer, M.-A., Antoine, M., Danel, C. J., Khalil, A., Cadranel, J. L., & Zalcman, G. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.010 · Cited by 41 · see citing works
Self-citationOrganizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma
Nakashima, K., Naito, T., Omori, S., Yoshikawa, S., Endo, M., Kiyohara, Y., & Takahashi, T. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.004 · Cited by 34 · see citing works
Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis
Kim, J. H., Je, J. H., Kim, S. H., Shin, D., Kim, T., Kim, D. Y., Kim, S. M., & Lee, M. (2015) · Archives of Dermatological Research · doi:10.1007/s00403-015-1588-5 · Cited by 29 · see citing works
Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings
Sakai, F., Johkoh, T., Kusumoto, M., et al. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0489-2 · Cited by 27 · see citing works
Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.
Konishi, J. S., Yamazaki, K., Kinoshita, I., et al. (2005) · PubMed · Cited by 26 · see citing works
Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
Hochstrasser, A., Benz, G., Joerger, M., et al. (2012) · Chemotherapy · doi:10.1159/000336131 · Cited by 21 · see citing works
Satake, N., Nagai, S., Kawatani, A., et al. (1993) · European Respiratory Journal · doi:10.1183/09031936.93.06040477 · Cited by 17 · see citing works
Pemetrexed-Induced Pneumonitis: A Case Report
Loriot, Y., Ferté, C., Gomez‐Roca, C., et al. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.050 · Cited by 13 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550.
Cited by
Sorted by citations
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992 · see citing works
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314 · see citing works
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29 · see citing works
- Authors
- Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., Planchard, D., Metivier, A.-C., Tomasini, P., Dansin, E., Pérol, M., Campana, M., Gautschi, O., Früh, M., Fumet, J.-D., Audigier-Valette, C., Couraud, S., Dalle, S., Leccia, M.-T., Jaffro, M., Collot, S., Prévot, G., Milia, J., & Mazieres, J.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut Claudius Regaud (FR)
- Institut Gustave Roussy (FR)
- Inserm (FR)
- Hospices Civils de Lyon (FR)
- Aix-Marseille Université (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Luzerner Kantonsspital (CH)
- Kantonsspital St. Gallen (CH)
- Centre Georges François Leclerc (FR)
- Hôpital Albert Michallon (FR)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1700050
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2744857567
- Cited by
- 412
- References
- 40
- Citations by year
- 2026: 16 · 2025: 40 · 2024: 55 · 2023: 51 · 2022: 56 · 2021: 52 · 2020: 71 · 2019: 36 · 2018: 30 · 2017: 4
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-11-09)
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- immune checkpoint inhibitors, interstitial lung disease, immune-related adverse events, PD-1 inhibitors, lung cancer, melanoma, ground-glass opacities, organizing pneumonia, hypersensitivity pneumonitis, radiological patterns, overall survival, immunotherapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, France, Humans, Immunotherapy, Lung, Male, Middle Aged, Neoplasms, Retrospective Studies, Risk Factors, Severity of Illness Index, Switzerland, Tomography, X-Ray Computed, Lung Diseases, Interstitial, Kaplan-Meier Estimate, Young Adult, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
